Telix sees more backing for LAT1
TLX101 follows Ipax-1 with an apparent success in an academic trial.
TLX101 follows Ipax-1 with an apparent success in an academic trial.
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
The German group has posted a PFS win in phase 3, but overall survival was confounded by crossover.
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.